Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 18/20 | 0.72 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.68 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.68 |
| ▸ | CSNK1G1 | Q9HCP0 | 3/20 | 0.68 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.68 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.68 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.68 |
| ▸ | GSK3A | P49840 | 1/20 | 0.68 |
| ▸ | GSK3B | P49841 | 1/20 | 0.68 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.68 |
| ▸ | PRKX | P51817 | 1/20 | 0.68 |
| ▸ | NEK4 | P51957 | 1/20 | 0.68 |
| ▸ | PLK1 | P53350 | 1/20 | 0.68 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.68 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.68 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16102053 | 1.00 | MAPKAPK2 (0.72) | MAPKAPK2AURKBPDGFRACSNK1G1ROCK1 | |
| SCHEMBL4366770 | 0.85 | MAPKAPK2 (0.72) | MAPKAPK2AURKBPDGFRACSNK1G1ROCK1 | |
| SCHEMBL4363960 | 0.84 | MAPKAPK2 (1.00) | MAPKAPK2AURKBPDGFRACSNK1G1ROCK1 | |
| SCHEMBL4378378 | 0.84 | MAPKAPK2 (1.00) | MAPKAPK2AURKBPDGFRACSNK1G1ROCK1 | |
| SCHEMBL4374212 | 0.83 | MAPKAPK2 (0.80) | MAPKAPK2AURKBPDGFRACSNK1G1ROCK1 | |
| SCHEMBL4366393 | 0.83 | MAPKAPK2 (0.69) | MAPKAPK2AURKBPDGFRACSNK1G1ROCK1 | |
| SCHEMBL4368799 | 0.82 | MAPKAPK2 (1.00) | MAPKAPK2AURKBPDGFRACSNK1G1ROCK1 | |
| SCHEMBL4371766 | 0.82 | MAPKAPK2 (0.91) | MAPKAPK2AURKBPDGFRACSNK1G1ROCK1 | |
| SCHEMBL4366478 | 0.82 | MAPKAPK2 (0.83) | MAPKAPK2AURKBPDGFRACSNK1G1ROCK1 | |
| SCHEMBL4368075 | 0.81 | MAPKAPK2 (1.00) | MAPKAPK2AURKBPDGFRACSNK1G1ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009012375-A2 | SQUARATE KINASE INHIBITORS | WYETH (US) | 2009-01-22 | — | — | WO | claimed |
| CN-110746424-A | MK2 inhibitors and uses thereof | 西建卡尔有限责任公司 | 2020-02-04 | — | — | CN | disclosed |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-09 | — | — | US | disclosed |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-09 | — | — | US | disclosed |
| US-10138256-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-11-27 | — | — | US | disclosed |
| EP-2968339-A1 | MK2 INHIBITORS AND USES THEREOF | Celgene Avilomics Research, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| WO-2014149164-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014149164-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2009012375-A2 | SQUARATE KINASE INHIBITORS | WYETH (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | MAPKAPK2 7/4885AURKB 144/4885PDGFRA 3451/4885 |
| US-10138256-B2 | MK2 inhibitors and uses thereof | MKNK2, DUSP2, MKNK1 | MAPKAPK2 7/4885AURKB 144/4885PDGFRA 3451/4885 |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | MAPKAPK2 7/4885AURKB 144/4885PDGFRA 3451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.